Global Consortium for Biomarker Standardization

The Alzheimer's Association has established the Global Consortium for Biomarker Standardization to gather key researchers, clinicians, and industry, regulatory and government leaders in Alzheimer's disease to achieve consensus on the best ways to standardize and validate biomarker tests for use in clinical practices around the world.

About the Global Consortium

Before these and other diagnostic measures can be incorporated into clinical practice worldwide, they must be standardized and validated on a global scale. The Global Consortium for Biomarker Standardization brings together these experts in teleconference and face-to-face meetings to address the challenges inherent in this goal and to develop the global scales required for worldwide implementation.

Related Projects

The Global Consortium for Biomarker Standardization will continue to grow and expand as the field identifies novel technologies and techniques for diagnosis of Alzheimer's disease. To date, there are projects addressing:

• Standardization of cerebrospinal fluid-based biomarkers including processing, handling, storage and measures. Currently, there are studies to assess the feasibility cross-culturally in the use of lumbar puncture techniques as a diagnostic.
  
• Harmonization of hippocampal volumetry changes that may diagnosis early stage Alzheimer's disease.

Meeting minutes and agendas

Next Meeting

AAIC 2013
July 13-18, 2013
Boston, Massachusetts, USA

Past Meetings

• Teleconference Meetings
• March 29, 2011
• Meeting minutes

• In Person Meetings
• July 14, 2012 (Vancouver, Canada)
• Agenda
• Meeting Minutes
• Alzheimer's Association QC Program - Niklas Mattsson
• Update MSD — Robert Umek & Pankaj Oberoi
• Update Innogenetics — Manu Vandijck
• Update Saladex - Spedaliere
• Ortho Clinical Diagnostics - Bittner
• Consituent/Diluent Agreement — Les Shaw, Rand Jenkins & Erin Chambers
• CAMD FDA Qualification Update — Diane Stephenson
• IRMM/IFCC Project Overview — Henrik Zetterberg
• July 15, 2011 (Paris, France)
• Agenda
• Meeting minutes
• July 15, 2010 (Honolulu, Hawaii)
• Agenda

Related papers and abstracts

• Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S et al. Alzheimer's & Dementia. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.  2011 Jul; 7/(4): 386-395 e6.
• Blennow K, Hampel H, Weiner M, Zetterberg H. Nature Review Neurology. Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. 2010 Mar: 6(3): 131-44. 
• Mattsson, Andreasson, Carrillo et al. Proficiency testing programs for Alzheimer’s disease cerebrospinal fluid biomarkers. Biomarkers M 404 ed. (2012) 6(4).
• Mattsson, Zegers, Andreasson et al. Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid b42Biomarkers Med. (2012) 6(4), 409–417.

For more information

For investigators who are interested in more information on the Global Consortium, including associated projects, past meetings or future meetings, please contact Maria C. Carrillo, Ph.D.

Maria C. Carrillo, Ph.D.
Vice President, Medical & Scientific Relations
Alzheimer's Association
maria.carrillo@alz.org